Rapid detection of methylglyoxal in blood samples
Award amount
$161,703Program and phase
SBIR · Phase IAward year
2013Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- BIOO SCIENTIFIC CORPORATION
- Proposal award date
- Not reported
- Contract end date
- Not reported
- UEI
- Z24GLNTRPBT5
- Solicitation number
- PA12-088
- Topic code
- NIDDK
Research abstract
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
- Sequencing of Epigenetic Modifications from Single Cells
- TARGETED THERAPEUTIC ANTIBODY MOLECULES AGAINST VIRAL ENCEPHALITIS
- Digital Gene Expression Analysis by 3’ End Sequencing
- Burkholderia antibody molecules for therapeutics and diagnostics
- SBIR Phase II: High-throughput Small RNA Sequencing
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.
- ND Enabling Studies for CMT-101, a Novel Gene Therapy for Glycogen Storage Disease 1b
- Wearable Metabolic Sensor for Monitoring of Lactate and Glucose for People with Diabetes
- Novel Over-the-Scope Platform for Control of Variceal Bleeding
- Tolerogenic Nanotherapy to Delay Type I Diabetes
- An intravascular Bioartificial Pancreas (iBAP)
Research funding history
26 SBIR/STTR records share this UEI (2007–2016). Reported award amounts total $7,244,135. Reported amounts are not federal obligations.
Phases: Phase I, Phase II
Agencies: Department of Health and Human Services, National Science Foundation, Department of Defense, Department of Agriculture